Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05923346
Other study ID # M10_2020_081 GLUTLEARN
Secondary ID GIU18/78GIU21/05
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2022
Est. completion date November 1, 2023

Study information

Verified date November 2023
Source University of the Basque Country (UPV/EHU)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Celiac disease (CD) is an autoimmune disease that occurs in people who are genetically predisposed to gluten consumption (1). The prevalence of the disease is about 1-2% and it is more common in women than in men, and in children than in adults (2). The only current treatment for celiac disease is a strict, lifelong gluten-free diet. This involves the complete elimination of gluten from the diet. Gluten is not only present in some cereals such as wheat, rye, barley and oats, but is also found in many foods that have been processed. In addition to being safe, the gluten-free diet must also be balanced. Following a gluten-free diet creates psychological and social problems for the people who have to follow it (3). It has been seen in several studies that people with celiac condition can feel different and excluded, as it is difficult to eat out, to make sure that the food is gluten-free and to avoid cross-contact (4-8). Due to the complicate situation of people with celiac disease, they do not hesitate to seek information about the management of their diseas. That is why people with celiac disease turn to social networks, as a rapid, visual and accessible way to share information (9-11). In line with the objectives of the University to which the Gluten3S research group belongs to (University of the Basque Country, UPV/EHU), the group has been aware for some time of the importance of disseminating science on social networks in order to make the results of the research reach the general public. It is considered that creating a nutritional education programme about CD and Gluten-Free Diet (GFD), delivered by experts in the field, could be useful in improving knowledge and attitudes about this matter. This will empower people with CD to improve their self-care and take control of their situation. Furthermore, it is also interesting to design the programme in such a way that the impact of the intervention can be measured, always with the intention of continuous improvement and reaching people with celiac disease and their environment in an effective way. The educational intervention will be carried out for one month and is aimed at adults with coeliac disease or adults with coeliac relatives who are involved in their care. Each day a post will be uploaded to Instagram with specific, accurate and current information. The content of the intervention has been divided into 5 main blocks: 1) general concepts about CD, 2) balanced GFD, 3) food labelling, 4) cross-contact/cross-contamination, 5) new research on CD and useful resources for disease management. The evaluation of the intervention will be carried out through pre- and post-intervention questionnaires.


Recruitment information / eligibility

Status Completed
Enrollment 93
Est. completion date November 1, 2023
Est. primary completion date November 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Be of legal age - Have celiac disease or be involved in the care of a person with celiac disease - Be an Instagram user

Study Design


Related Conditions & MeSH terms


Intervention

Other:
GLUTLEARN
The group will be made up of users of the social network Instagram who have celiac disease or are close to a celiac patient (parent/guardian of celiac children or cohabitants). The intervention will be carried out through the social network Instagram. Participants will be recruited through the same social network. Participants must agree to take part in the study. The educational intervention will be carried out for one month, where each day a "post" will be uploaded with specific, truthful and current information. The content of the intervention has been divided into 5 main blocks: 1) general concepts about CD, 2) balanced GFD, 3) food labelling, 4) cross-contact/cross-contamination, 5) new research on CD and useful resources for disease management.

Locations

Country Name City State
Spain University of the Basque Country (UPV/EHU) Vitoria-Gasteiz Álava

Sponsors (1)

Lead Sponsor Collaborator
University of the Basque Country (UPV/EHU)

Country where clinical trial is conducted

Spain, 

References & Publications (12)

Al Sarkhy A. Social media usage pattern and its influencing factors among celiac patients and their families. Saudi J Gastroenterol. 2020 Mar-Apr;26(2):99-104. doi: 10.4103/sjg.SJG_495_19. — View Citation

Cadenhead JW, Wolf RL, Lebwohl B, Lee AR, Zybert P, Reilly NR, Schebendach J, Satherley R, Green PHR. Diminished quality of life among adolescents with coeliac disease using maladaptive eating behaviours to manage a gluten-free diet: a cross-sectional, mixed-methods study. J Hum Nutr Diet. 2019 Jun;32(3):311-320. doi: 10.1111/jhn.12638. Epub 2019 Mar 5. — View Citation

Itzlinger A, Branchi F, Elli L, Schumann M. Gluten-Free Diet in Celiac Disease-Forever and for All? Nutrients. 2018 Nov 18;10(11):1796. doi: 10.3390/nu10111796. — View Citation

Lebwohl B, Rubio-Tapia A. Epidemiology, Presentation, and Diagnosis of Celiac Disease. Gastroenterology. 2021 Jan;160(1):63-75. doi: 10.1053/j.gastro.2020.06.098. Epub 2020 Sep 18. — View Citation

McNally SL, Donohue MC, Newton KP, Ogletree SP, Conner KK, Ingegneri SE, Kagnoff MF. Can consumers trust web-based information about celiac disease? Accuracy, comprehensiveness, transparency, and readability of information on the internet. Interact J Med Res. 2012 Apr 4;1(1):e1. doi: 10.2196/ijmr.2010. — View Citation

Olsson C, Lyon P, Hornell A, Ivarsson A, Sydner YM. Food that makes you different: the stigma experienced by adolescents with celiac disease. Qual Health Res. 2009 Jul;19(7):976-84. doi: 10.1177/1049732309338722. — View Citation

Rosen A, Ivarsson A, Nordyke K, Karlsson E, Carlsson A, Danielsson L, Hogberg L, Emmelin M. Balancing health benefits and social sacrifices: a qualitative study of how screening-detected celiac disease impacts adolescents' quality of life. BMC Pediatr. 2011 May 10;11:32. doi: 10.1186/1471-2431-11-32. — View Citation

Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, Kelly CP, Ahuja V, Makharia GK. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018 Jun;16(6):823-836.e2. doi: 10.1016/j.cgh.2017.06.037. Epub 2018 Mar 16. — View Citation

Singh P, Dennis M. Eliminating Dietary Gluten: Don't Be a "Glutton for Punishment". Dig Dis Sci. 2018 Jun;63(6):1374-1375. doi: 10.1007/s10620-018-5010-y. No abstract available. — View Citation

Trovato CM, Montuori M, Oliva S, Cucchiara S, Cignarelli A, Sansone A. Assessment of public perceptions and concerns of celiac disease: A Twitter-based sentiment analysis study. Dig Liver Dis. 2020 Apr;52(4):464-466. doi: 10.1016/j.dld.2020.02.004. Epub 2020 Feb 29. No abstract available. — View Citation

Vazquez-Polo M, Navarro V, Larretxi I, Perez-Junkera G, Lasa A, Matias S, Simon E, Churruca I. Uncovering the Concerns and Needs of Individuals with Celiac Disease: A Cross-Sectional Study. Nutrients. 2023 Aug 22;15(17):3681. doi: 10.3390/nu15173681. — View Citation

Wolf RL, Lebwohl B, Lee AR, Zybert P, Reilly NR, Cadenhead J, Amengual C, Green PHR. Hypervigilance to a Gluten-Free Diet and Decreased Quality of Life in Teenagers and Adults with Celiac Disease. Dig Dis Sci. 2018 Jun;63(6):1438-1448. doi: 10.1007/s10620-018-4936-4. Epub 2018 Jan 31. Erratum In: Dig Dis Sci. 2018 Apr 11;: — View Citation

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Knowledge regarding celiac disease A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test) in order to assess changes due to the intervention.The unit of measure will be the score obtained in the questionnaires (0, worst-1,best/0, disagree-4,agree/the number of correct answers). 5 weeks
Primary Attitude towards celiac disease: degree of concern A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test) in order to assess changes due to the intervention.The unit of measure will be the score obtained in the questionnaires (0, worst-1,best/0, disagree-4,agree/the number of correct answers). 5 weeks
Primary Knowledge regarding balanced GFD A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test) in order to assess changes due to the intervention.The unit of measure will be the score obtained in the questionnaires (0, worst-1,best/0, disagree-4,agree/the number of correct answers). 5 weeks
Primary Knowledge regarding food labels A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test) in order to assess changes due to the intervention.The unit of measure will be the score obtained in the questionnaires (0, worst-1,best/0, disagree-4,agree/the number of correct answers). 5 weeks
Primary Attitude: degree of confidence in their choice of food A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test) in order to assess changes due to the intervention.The unit of measure will be the score obtained in the questionnaires (0, worst-1,best/0, disagree-4,agree/the number of correct answers). 5 weeks
Primary Knowledge regarding cross-contact A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test) in order to assess changes due to the intervention.The unit of measure will be the score obtained in the questionnaires (0, worst-1,best/0, disagree-4,agree/the number of correct answers). 5 weeks
Primary Attitude: degree of confidence in avoiding cross-contact A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test) in order to assess changes due to the intervention.The unit of measure will be the score obtained in the questionnaires (0, worst-1,best/0, disagree-4,agree/the number of correct answers). 5 weeks
Primary Knowledge regarding new research in CD A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test) in order to assess changes due to the intervention.The unit of measure will be the score obtained in the questionnaires (0, worst-1,best/0, disagree-4,agree/the number of correct answers). 5 weeks
Secondary Satisfaction about the education received A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test). Secondary outcomes will be measured in the post-questionnaire. • The unit of measure will be the score obtained in the questionnaires (0, disagree-4,agree). Immediately after the intervention
Secondary Perception of the importance of educational activities A questionnaire will be used to be able to assess all outcomes. The same questionnaire will be completed twice, once before the intervention (pre-test) and again immediately after the end of the intervention (post-test). Secondary outcomes will be measured in the post-questionnaire. • The unit of measure will be the score obtained in the questionnaires (0, disagree-4,agree). Immediately after the intervention
See also
  Status Clinical Trial Phase
Completed NCT04349904 - Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Completed NCT04593251 - Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis Phase 1
Completed NCT05810441 - Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
Recruiting NCT05555446 - Bovine Colostrum to Prevent Absorption of Gluten Early Phase 1
Completed NCT02754609 - Hookworm Therapy for Coeliac Disease Phase 1
Terminated NCT01902368 - Celiac Disease Screening N/A
Completed NCT02472704 - Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo N/A
Completed NCT02312349 - Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
Completed NCT01172665 - Celiac Disease Database
Completed NCT01100099 - HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease Phase 2/Phase 3
Completed NCT00639444 - Risk of Celiac Disease and Age at Gluten Introduction N/A
Active, not recruiting NCT05425446 - Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients Phase 1
Enrolling by invitation NCT02202681 - Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule N/A
Completed NCT00362856 - Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects Phase 2
Terminated NCT03866538 - Budesonide in Patients With Immune Mediated Enteropathies Phase 4
Recruiting NCT05135923 - Glutenfree, Gut Microbiota and Metabolic Regulation N/A
Completed NCT05052164 - Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women N/A
Completed NCT03775499 - Probiotic BL NCC 2705 and Gluten Sensitivity N/A
Completed NCT03707730 - A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease Phase 2